Ocular Therapeutix Announces Successful Completion of Study of Sustained Drug Delivery Moxifloxacin Punctum Plug
October 14, 2010
Submit Comments
Ocular Therapeutix, Inc. announced the successful completion of a clinical study of their sustained drug delivery moxifloxacin punctum plug. The study was a single-site, single-armed, single-dose study in which 10 patients received the punctum plug immediately following cataract surgery and were evaluated over a 10-day period.
Primary outcome measures were plug retention and moxifloxacin levels above the minimum concentration to stop growth in various strains of bacterial conjunctivitis.
Click here to read the full press release.
You might also enjoy...
- Clinical Trial of Pink Eye Test to Commence in Fall
- QLT Announces Phase II Clinical Trial Results for the Olopatadine Punctal Plug Delivery System
- Merck Acquiring Inspire Pharmaceuticals
- Should a Child With Conjunctivitis Stay Home?
- QLT Announces Interim Data for Phase 2 Punctal Plug Delivery System Clinical Trial
Comments
Jump down to form below to submit your own comments
